Tarlatamab

SEP 9, 2026 · PHASE 2 TRIAL

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 2 study with no results reported; it documents study design and biomarker strategy but carries no efficacy or safety data.

SEP 8, 2026 · PHASE 3 TRIAL

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

ClinicalTrials.gov

This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.

SEP 4, 2026 · PHASE 2 TRIAL

Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status

ClinicalTrials.gov

This is a Phase 2 clinical trial registry record with no results posted; the study is currently recruiting and has not yet generated efficacy or safety data.

AUG 19, 2026 · PHASE 2 TRIAL

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

ClinicalTrials.gov

This is a registry record of an ongoing Phase 2 single-arm trial with no results posted; it describes planned conduct and endpoints only.